564 related articles for article (PubMed ID: 28507129)
1. Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models.
Irukayama-Tomobe Y; Ogawa Y; Tominaga H; Ishikawa Y; Hosokawa N; Ambai S; Kawabe Y; Uchida S; Nakajima R; Saitoh T; Kanda T; Vogt K; Sakurai T; Nagase H; Yanagisawa M
Proc Natl Acad Sci U S A; 2017 May; 114(22):5731-5736. PubMed ID: 28507129
[TBL] [Abstract][Full Text] [Related]
2. [Development of a Therapeutic Drug for Narcolepsy].
Irukayama-Tomobe Y; Yanagisawa M
Brain Nerve; 2018 Nov; 70(11):1255-1263. PubMed ID: 30416119
[TBL] [Abstract][Full Text] [Related]
3. TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy.
Ishikawa T; Hara H; Kawano A; Tohyama K; Kajita Y; Miyanohana Y; Koike T; Kimura H
J Pharmacol Exp Ther; 2023 Jun; 385(3):193-204. PubMed ID: 37001988
[TBL] [Abstract][Full Text] [Related]
4. OX2R-selective orexin agonism is sufficient to ameliorate cataplexy and sleep/wake fragmentation without inducing drug-seeking behavior in mouse model of narcolepsy.
Yamamoto H; Nagumo Y; Ishikawa Y; Irukayama-Tomobe Y; Namekawa Y; Nemoto T; Tanaka H; Takahashi G; Tokuda A; Saitoh T; Nagase H; Funato H; Yanagisawa M
PLoS One; 2022; 17(7):e0271901. PubMed ID: 35867683
[TBL] [Abstract][Full Text] [Related]
5. Continuous intrathecal orexin delivery inhibits cataplexy in a murine model of narcolepsy.
Kaushik MK; Aritake K; Imanishi A; Kanbayashi T; Ichikawa T; Shimizu T; Urade Y; Yanagisawa M
Proc Natl Acad Sci U S A; 2018 Jun; 115(23):6046-6051. PubMed ID: 29784823
[TBL] [Abstract][Full Text] [Related]
6. TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice.
Yukitake H; Fujimoto T; Ishikawa T; Suzuki A; Shimizu Y; Rikimaru K; Ito M; Suzuki M; Kimura H
Pharmacol Biochem Behav; 2019 Dec; 187():172794. PubMed ID: 31654653
[TBL] [Abstract][Full Text] [Related]
7. Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients.
Evans R; Kimura H; Alexander R; Davies CH; Faessel H; Hartman DS; Ishikawa T; Ratti E; Shimizu K; Suzuki M; Tanaka S; Yukitake H; Dauvilliers Y; Mignot E
Proc Natl Acad Sci U S A; 2022 Aug; 119(35):e2207531119. PubMed ID: 35994639
[TBL] [Abstract][Full Text] [Related]
8. Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists.
Nagahara T; Saitoh T; Kutsumura N; Irukayama-Tomobe Y; Ogawa Y; Kuroda D; Gouda H; Kumagai H; Fujii H; Yanagisawa M; Nagase H
J Med Chem; 2015 Oct; 58(20):7931-7. PubMed ID: 26267383
[TBL] [Abstract][Full Text] [Related]
9. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes.
Willie JT; Chemelli RM; Sinton CM; Tokita S; Williams SC; Kisanuki YY; Marcus JN; Lee C; Elmquist JK; Kohlmeier KA; Leonard CS; Richardson JA; Hammer RE; Yanagisawa M
Neuron; 2003 Jun; 38(5):715-30. PubMed ID: 12797957
[TBL] [Abstract][Full Text] [Related]
10. Trace Amine-Associated Receptor 1 Agonists as Narcolepsy Therapeutics.
Black SW; Schwartz MD; Chen TM; Hoener MC; Kilduff TS
Biol Psychiatry; 2017 Nov; 82(9):623-633. PubMed ID: 27919403
[TBL] [Abstract][Full Text] [Related]
11. Danavorexton, a selective orexin 2 receptor agonist, provides a symptomatic improvement in a narcolepsy mouse model.
Ishikawa T; Hara H; Kawano A; Kimura H
Pharmacol Biochem Behav; 2022 Oct; 220():173464. PubMed ID: 36108771
[TBL] [Abstract][Full Text] [Related]
12. Wake-promoting effects of ONO-4127Na, a prostaglandin DP1 receptor antagonist, in hypocretin/orexin deficient narcoleptic mice.
Sagawa Y; Sato M; Sakai N; Chikahisa S; Chiba S; Maruyama T; Yamamoto J; Nishino S
Neuropharmacology; 2016 Nov; 110(Pt A):268-276. PubMed ID: 27474349
[TBL] [Abstract][Full Text] [Related]
13. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice.
Mieda M; Willie JT; Hara J; Sinton CM; Sakurai T; Yanagisawa M
Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4649-54. PubMed ID: 15070772
[TBL] [Abstract][Full Text] [Related]
14. Orexin neurons suppress narcolepsy via 2 distinct efferent pathways.
Hasegawa E; Yanagisawa M; Sakurai T; Mieda M
J Clin Invest; 2014 Feb; 124(2):604-16. PubMed ID: 24382351
[TBL] [Abstract][Full Text] [Related]
15. Induction of narcolepsy-like symptoms by orexin receptor antagonists in mice.
Kaushik MK; Aritake K; Cherasse Y; Imanishi A; Kanbayashi T; Urade Y; Yanagisawa M
Sleep; 2021 Aug; 44(8):. PubMed ID: 33609365
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Arylsulfonamides as Dual Orexin Receptor Agonists.
Zhang D; Perrey DA; Decker AM; Langston TL; Mavanji V; Harris DL; Kotz CM; Zhang Y
J Med Chem; 2021 Jun; 64(12):8806-8825. PubMed ID: 34101446
[TBL] [Abstract][Full Text] [Related]
17. Toward the Mysteries of Sleep.
Yanagisawa M
Keio J Med; 2019; 68(1):27. PubMed ID: 30905886
[TBL] [Abstract][Full Text] [Related]
18. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
Hoyer D; Jacobson LH
Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
[TBL] [Abstract][Full Text] [Related]
19. Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation.
Nirogi R; Benade V; Daripelli S; Subramanian R; Kamuju V; Bhyrapuneni G; Muddana NR; Mekala VR; Petlu S; Jayarajan P; Badange R; Shinde A; Jasti V
Psychopharmacology (Berl); 2021 Jun; 238(6):1495-1511. PubMed ID: 33550481
[TBL] [Abstract][Full Text] [Related]
20. An overview of hypocretin based therapy in narcolepsy.
Takenoshita S; Sakai N; Chiba Y; Matsumura M; Yamaguchi M; Nishino S
Expert Opin Investig Drugs; 2018 Apr; 27(4):389-406. PubMed ID: 29623725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
